tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

RXRX Stock Latest News

Private Markets: Anthropic projects $70B in revenue in 2028
The FlyPrivate Markets: Anthropic projects $70B in revenue in 2028
6d ago
S
BMY
Recursion Pharmaceuticals’ Earnings Call Highlights Growth and Challenges
PremiumCompany Announcements
Recursion Pharmaceuticals’ Earnings Call Highlights Growth and Challenges
7d ago
RXRX
Recursion Pharmaceuticals: Q3 2025 Financial Highlights
PremiumCompany Announcements
Recursion Pharmaceuticals: Q3 2025 Financial Highlights
8d ago
RXRX
Strong Financial Position and Strategic Leadership Drive Buy Rating for Recursion Pharmaceuticals
PremiumRatings
Strong Financial Position and Strategic Leadership Drive Buy Rating for Recursion Pharmaceuticals
8d ago
RXRX
Recursion Pharmaceuticals: Advancements and Leadership Transition Lead to Hold Rating
PremiumRatings
Recursion Pharmaceuticals: Advancements and Leadership Transition Lead to Hold Rating
8d ago
RXRX
Recursion Pharmaceuticals Announces New CEO Appointment
PremiumCompany AnnouncementsRecursion Pharmaceuticals Announces New CEO Appointment
9d ago
8K
RXRX
Recursion Pharmaceuticals reports Q3 EPS (36c), consensus (38c)
Premium
The Fly
Recursion Pharmaceuticals reports Q3 EPS (36c), consensus (38c)
9d ago
RXRX
Recursion appoints Najat Khan as CEO, effective January 1
Premium
The Fly
Recursion appoints Najat Khan as CEO, effective January 1
9d ago
RXRX
Roche Exercises Option with Recursion Pharmaceuticals
PremiumCompany Announcements
Roche Exercises Option with Recursion Pharmaceuticals
16d ago
8K
RXRX
Recursion Pharmaceuticals Advances REC-4881 Study for Familial Adenomatous Polyposis
PremiumCompany Announcements
Recursion Pharmaceuticals Advances REC-4881 Study for Familial Adenomatous Polyposis
17d ago
RXRX
Recursion Pharmaceuticals Advances with REC-1245 Cancer Study
PremiumCompany Announcements
Recursion Pharmaceuticals Advances with REC-1245 Cancer Study
17d ago
RXRX
Recursion Pharmaceuticals call volume above normal and directionally bullish
PremiumThe Fly
Recursion Pharmaceuticals call volume above normal and directionally bullish
25d ago
RXRX
Unusually active option classes on open October 20th
PremiumThe FlyUnusually active option classes on open October 20th
25d ago
AUR
CAN
Recursion Pharmaceuticals call volume above normal and directionally bullish
Premium
The Fly
Recursion Pharmaceuticals call volume above normal and directionally bullish
29d ago
RXRX
Recursion Pharmaceuticals call volume above normal and directionally bullish
Premium
The Fly
Recursion Pharmaceuticals call volume above normal and directionally bullish
1M ago
RXRX
Recursion Pharmaceuticals rises 17.9%
PremiumThe Fly
Recursion Pharmaceuticals rises 17.9%
1M ago
RXRX
Unusually active option classes on open September 25th
PremiumThe Fly
Unusually active option classes on open September 25th
2M ago
BB
ACN
Strategic Growth and Unique Positioning Drive Buy Rating for Recursion Pharmaceuticals
PremiumRatings
Strategic Growth and Unique Positioning Drive Buy Rating for Recursion Pharmaceuticals
2M ago
RXRX
Recursion Pharmaceuticals management to meet with Needham
PremiumThe Fly
Recursion Pharmaceuticals management to meet with Needham
2M ago
RXRX
Buy Recommendation for Recursion Pharmaceuticals: Strong Position in AI-Driven Drug Discovery with Strategic Acquisitions and Financial Stability
PremiumRatingsBuy Recommendation for Recursion Pharmaceuticals: Strong Position in AI-Driven Drug Discovery with Strategic Acquisitions and Financial Stability
2M ago
RXRX
Private Markets: Anthropic raises $13B Series F at $183B post-money valuation
Premium
The Fly
Private Markets: Anthropic raises $13B Series F at $183B post-money valuation
2M ago
AI
GS
Rallybio receives $12.5M equity milestone payment from Recursion Pharmaceuticals
Premium
The Fly
Rallybio receives $12.5M equity milestone payment from Recursion Pharmaceuticals
2M ago
RLYB
RXRX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >